Trends in Treatment and Survival in Older Patients Presenting with Stage IV Colorectal Cancer

Gabriela M. Vargas, Kristin M. Sheffield, Abhishek D. Parmar, Yimei Han, Aakash Gajjar, Kimberly M. Brown, Taylor S. Riall

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Introduction: Trends in the use of modern chemotherapeutic regimens, primary tumor resection, and the timing of chemotherapy and resection in older patients with stage IV colorectal cancer have not been evaluated. Methods: We used Cancer Registry- and Medicare-linked data (2000-2009) to describe time trends in resection of the primary tumor and receipt of chemotherapy in patients ≥66 presenting with stage IV colorectal cancer (N = 16,168). Results: The mean age was 77.8 ± 7.3 years; 53.8 % were women and 82.9 % were white. Primary cancer sites were colon in 83.4 % and rectum in 16.6 %. Resection of the primary tumor decreased from 64.6 to 57.1 % (P < 0.0001) from 2001 to 2009. Systemic chemotherapy was given to 45.1 % of the patients. While the use of chemotherapy was stable over time (P = 0.48), the use of modern regimens containing oxaliplatin or irinotecan increased from 40.9 to 75.4 % (P < 0.0001). Bevacizumab use increased from 0.10 to 54.2 % (P < 0.0001). Survival improved by 4 % per year even after controlling for treatment and tumor location (HR = 0.96, 95 % CI 0.95-0.97). Conclusions: Survival in older patients with stage IV disease is improving over time. Surgical resection is still performed in the majority of patients. Resection rates decreased while modern chemotherapy was rapidly adopted perhaps suggesting a shift in practice patterns.

Original languageEnglish (US)
Pages (from-to)369-377
Number of pages9
JournalJournal of Gastrointestinal Surgery
Volume18
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

Colorectal Neoplasms
Survival
Drug Therapy
Neoplasms
oxaliplatin
irinotecan
Therapeutics
Medicare
Rectum
Registries
Colon

Keywords

  • Cancer therapy
  • Colorectal cancer
  • Oncology
  • Stage IV cancer

ASJC Scopus subject areas

  • Surgery
  • Gastroenterology

Cite this

Vargas, G. M., Sheffield, K. M., Parmar, A. D., Han, Y., Gajjar, A., Brown, K. M., & Riall, T. S. (2014). Trends in Treatment and Survival in Older Patients Presenting with Stage IV Colorectal Cancer. Journal of Gastrointestinal Surgery, 18(2), 369-377. https://doi.org/10.1007/s11605-013-2406-z

Trends in Treatment and Survival in Older Patients Presenting with Stage IV Colorectal Cancer. / Vargas, Gabriela M.; Sheffield, Kristin M.; Parmar, Abhishek D.; Han, Yimei; Gajjar, Aakash; Brown, Kimberly M.; Riall, Taylor S.

In: Journal of Gastrointestinal Surgery, Vol. 18, No. 2, 02.2014, p. 369-377.

Research output: Contribution to journalArticle

Vargas, GM, Sheffield, KM, Parmar, AD, Han, Y, Gajjar, A, Brown, KM & Riall, TS 2014, 'Trends in Treatment and Survival in Older Patients Presenting with Stage IV Colorectal Cancer', Journal of Gastrointestinal Surgery, vol. 18, no. 2, pp. 369-377. https://doi.org/10.1007/s11605-013-2406-z
Vargas, Gabriela M. ; Sheffield, Kristin M. ; Parmar, Abhishek D. ; Han, Yimei ; Gajjar, Aakash ; Brown, Kimberly M. ; Riall, Taylor S. / Trends in Treatment and Survival in Older Patients Presenting with Stage IV Colorectal Cancer. In: Journal of Gastrointestinal Surgery. 2014 ; Vol. 18, No. 2. pp. 369-377.
@article{9600a985a7074a5fa653a53552072ff5,
title = "Trends in Treatment and Survival in Older Patients Presenting with Stage IV Colorectal Cancer",
abstract = "Introduction: Trends in the use of modern chemotherapeutic regimens, primary tumor resection, and the timing of chemotherapy and resection in older patients with stage IV colorectal cancer have not been evaluated. Methods: We used Cancer Registry- and Medicare-linked data (2000-2009) to describe time trends in resection of the primary tumor and receipt of chemotherapy in patients ≥66 presenting with stage IV colorectal cancer (N = 16,168). Results: The mean age was 77.8 ± 7.3 years; 53.8 {\%} were women and 82.9 {\%} were white. Primary cancer sites were colon in 83.4 {\%} and rectum in 16.6 {\%}. Resection of the primary tumor decreased from 64.6 to 57.1 {\%} (P < 0.0001) from 2001 to 2009. Systemic chemotherapy was given to 45.1 {\%} of the patients. While the use of chemotherapy was stable over time (P = 0.48), the use of modern regimens containing oxaliplatin or irinotecan increased from 40.9 to 75.4 {\%} (P < 0.0001). Bevacizumab use increased from 0.10 to 54.2 {\%} (P < 0.0001). Survival improved by 4 {\%} per year even after controlling for treatment and tumor location (HR = 0.96, 95 {\%} CI 0.95-0.97). Conclusions: Survival in older patients with stage IV disease is improving over time. Surgical resection is still performed in the majority of patients. Resection rates decreased while modern chemotherapy was rapidly adopted perhaps suggesting a shift in practice patterns.",
keywords = "Cancer therapy, Colorectal cancer, Oncology, Stage IV cancer",
author = "Vargas, {Gabriela M.} and Sheffield, {Kristin M.} and Parmar, {Abhishek D.} and Yimei Han and Aakash Gajjar and Brown, {Kimberly M.} and Riall, {Taylor S.}",
year = "2014",
month = "2",
doi = "10.1007/s11605-013-2406-z",
language = "English (US)",
volume = "18",
pages = "369--377",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Trends in Treatment and Survival in Older Patients Presenting with Stage IV Colorectal Cancer

AU - Vargas, Gabriela M.

AU - Sheffield, Kristin M.

AU - Parmar, Abhishek D.

AU - Han, Yimei

AU - Gajjar, Aakash

AU - Brown, Kimberly M.

AU - Riall, Taylor S.

PY - 2014/2

Y1 - 2014/2

N2 - Introduction: Trends in the use of modern chemotherapeutic regimens, primary tumor resection, and the timing of chemotherapy and resection in older patients with stage IV colorectal cancer have not been evaluated. Methods: We used Cancer Registry- and Medicare-linked data (2000-2009) to describe time trends in resection of the primary tumor and receipt of chemotherapy in patients ≥66 presenting with stage IV colorectal cancer (N = 16,168). Results: The mean age was 77.8 ± 7.3 years; 53.8 % were women and 82.9 % were white. Primary cancer sites were colon in 83.4 % and rectum in 16.6 %. Resection of the primary tumor decreased from 64.6 to 57.1 % (P < 0.0001) from 2001 to 2009. Systemic chemotherapy was given to 45.1 % of the patients. While the use of chemotherapy was stable over time (P = 0.48), the use of modern regimens containing oxaliplatin or irinotecan increased from 40.9 to 75.4 % (P < 0.0001). Bevacizumab use increased from 0.10 to 54.2 % (P < 0.0001). Survival improved by 4 % per year even after controlling for treatment and tumor location (HR = 0.96, 95 % CI 0.95-0.97). Conclusions: Survival in older patients with stage IV disease is improving over time. Surgical resection is still performed in the majority of patients. Resection rates decreased while modern chemotherapy was rapidly adopted perhaps suggesting a shift in practice patterns.

AB - Introduction: Trends in the use of modern chemotherapeutic regimens, primary tumor resection, and the timing of chemotherapy and resection in older patients with stage IV colorectal cancer have not been evaluated. Methods: We used Cancer Registry- and Medicare-linked data (2000-2009) to describe time trends in resection of the primary tumor and receipt of chemotherapy in patients ≥66 presenting with stage IV colorectal cancer (N = 16,168). Results: The mean age was 77.8 ± 7.3 years; 53.8 % were women and 82.9 % were white. Primary cancer sites were colon in 83.4 % and rectum in 16.6 %. Resection of the primary tumor decreased from 64.6 to 57.1 % (P < 0.0001) from 2001 to 2009. Systemic chemotherapy was given to 45.1 % of the patients. While the use of chemotherapy was stable over time (P = 0.48), the use of modern regimens containing oxaliplatin or irinotecan increased from 40.9 to 75.4 % (P < 0.0001). Bevacizumab use increased from 0.10 to 54.2 % (P < 0.0001). Survival improved by 4 % per year even after controlling for treatment and tumor location (HR = 0.96, 95 % CI 0.95-0.97). Conclusions: Survival in older patients with stage IV disease is improving over time. Surgical resection is still performed in the majority of patients. Resection rates decreased while modern chemotherapy was rapidly adopted perhaps suggesting a shift in practice patterns.

KW - Cancer therapy

KW - Colorectal cancer

KW - Oncology

KW - Stage IV cancer

UR - http://www.scopus.com/inward/record.url?scp=84895903833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895903833&partnerID=8YFLogxK

U2 - 10.1007/s11605-013-2406-z

DO - 10.1007/s11605-013-2406-z

M3 - Article

VL - 18

SP - 369

EP - 377

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 2

ER -